Galegenimab, a newly developed antibody , is creating considerable anticipation within the cancer community. This groundbreaking drug functions as an blocker of TIGIT, a checkpoint protein, which plays a https://bookmarks-hit.com/story26028633/galegenimab-a-novel-possibility-in-cancer-treatment